US Stock Alert: Immutep plunges 74.6% pre-market as lung cancer trial terminated due to efficacy and safety data review

格隆汇 March 13｜Biotechnology company Immutep plunged 74.6% in pre-market trading. According to reports, Immutep will terminate its lung cancer trial due to the results of the review of efficacy and safety data. The document shows that the committee's recommendation was made after reviewing the existing safety and efficacy data. The document states that the study is evaluating the efficacy of eftilagimod alfa in first-line non-small cell lung cancer patients. In response to the committee's recommendation, the company will halt patient recruitment and gradually wind down the study.